Developer docs
API playgroundTry for free, no card

Search company profiles

Anova Enterprises

Full company profile

uuid0000ot4

Namestring
Anova Enterprises
Legal namestring
Anova Enterprises, Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Anova Enterprises is a privately held, technology-enabled contract research organization (CRO) founded in 2017 and headquartered in Schaumburg, Illinois, with an additional UK office in London. The company operates the AnovaOS™ platform, an integrated clinical research network that connects 15,000+ sponsors, 130,000+ active studies, 15,000+ investigational products, 40,000+ research sites, and 100,000+ investigators, with the stated goal of accelerating clinical development for oncology, neurology, urology, infectious disease, immunology, cardiology, and rare disease therapeutics.

The AnovaOS platform comprises interconnected modules covering protocol structuring and eligibility codification, site and physician qualification, patient matching, site activation (advertised as 5 working days via master contract and fee schedule), data capture, and essential document management. In 2025, the company launched a free AI-enabled patient matching solution covering 200,000+ open trials and a 21 CFR Part 11 compliant Global Clinical Registry, and scaled a Virtual Urology Research Network to 500+ active sites. The platform is HIPAA and 21 CFR Part 11 compliant, supporting both interventional trials and compassionate use programs.

Anova's business model combines enterprise services and platform subscriptions targeted at biopharmaceutical sponsors and CROs, complemented by a self-serve, free AI patient-matching funnel for patients and individual research sites. Pricing is quote-based and not publicly disclosed. The company generates revenue through technology-enabled CRO engagements, including ongoing programs with Denovo Biopharma (DB107 gene therapy in high-grade glioma, supported by an $11.8M CIRM grant), NeOnc Technologies (NEO212, NEO100), and Dizal Pharmaceuticals (DZD9008 for EGFR Exon20ins NSCLC). Leadership includes co-founders Chris Beardmore (CEO) and Martin Walsh (President), with senior executives added in 2025 including CMO Dr. Fred Ma, VP Clinical Development Adam Callahan, and CFO Rhonda Rosen.

Short descriptiontext

Anova Enterprises is a technology-enabled CRO operating the AnovaOS™ platform, which connects biopharma sponsors, research sites, and patients to accelerate clinical trial design, site activation, patient matching, and enrollment across oncology, neurology, urology, and rare diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersArlington Heights, United States
HQ citystring
Arlington Heights
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical trial technology, patient matching platform, contract research services, clinical site activation, real-world evidence registry
Industry4 codes
PRIMARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Custom Computer Programming Services541511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Management Consulting Services8742
Product category
Clinical Trial Technology
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1AnovaOS
Description

Proprietary clinical research technology platform providing an integrated research network of sponsors, studies, investigational products, research sites, and investigators. Enables patient matching, site activation, and clinical trial management.

anovaevidence.com
Core offering1 text field

Anova Enterprises operates AnovaOS™, a proprietary technology-enabled CRO platform that connects biopharmaceutical sponsors, research sites, physicians, and patients to accelerate clinical development. The platform delivers AI-enabled patient matching, digital feasibility assessments, automated site activation, remote monitoring, document/data management, and a global clinical registry across an integrated network of 40,000+ research sites and 100,000+ investigators. Anova supplements the platform with full-service CRO engagements and consulting for therapeutic areas including oncology, neurology, immunology, cardiology, infectious disease, and rare disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Free AI-enabled patient matching solution available to patients
Product overview1 text field

Anova Enterprises offers AnovaOS™, a unified clinical research technology platform that integrates an ecosystem of sponsors, research sites, physicians, and patients for accelerated clinical development. The platform comprises multiple interconnected modules including patient matching and enrollment, site activation, data capture and evidence generation, essential document management, and a global clinical registry. Additional offerings include a free AI-enabled patient matching solution using proprietary algorithms, a Network Powered Patient Registry study (NCT05013944) for real-world evidence, and a Virtual Urology Research Network sub-network with 500+ sites. The platform supports both clinical trials and compassionate use programs, enabling just-in-time access to any investigational product.

Product and service6 records
1AnovaOS™ Platform
CategoryClinical Trial Technology Platform
Description

Clinical research technology platform providing an integrated research network that connects sponsors, research sites, physicians, and patients. Enables study feasibility, patient matching, site activation, patient enrollment, data capture, and compassionate use program management for biopharmaceutical sponsors and research sites.

2AnovaOS® Global Clinical Registry
CategoryClinical Trial Technology Platform
Description

21 CFR Part 11 compliant global clinical registry providing real-world evidence about research sites and patients, administrative efficiency in research conduct, post-market surveillance, and data-driven study design support for sponsors and research sites.

3AI-Enabled Patient Matching Solution
CategoryPatient Matching Technology
Description

Free AI-powered patient matching solution using proprietary algorithms to connect patients to over 200,000+ open clinical trials with high-confidence eligibility matching. Automates screening and integrates into study coordination workflows for patients and participating research sites.

4Network Powered Patient Registry
CategoryReal-World Evidence Registry
Description

Global patient registry study (NCT05013944) capturing clinically meaningful real-world data on patient diagnosis, nature, course of infection, treatment(s), and outcomes for patients with complex and rare diseases, available to sponsors and research sites through the AnovaOS network.

5Virtual Urology Research Network
CategorySpecialty Research Network
Description

Virtual urology research network of 500+ quality-confirmed research sites enabling rapid site-to-study matching, streamlined study start-up, and faster patient enrollment for urology clinical research programs.

6Clinical Development & Technical Consulting Services
CategoryCRO Consulting Services
Description

Consultancy services to accelerate clinical development and technical services for data integration, advanced analytics, and clinical evidence generation for biopharmaceutical sponsors and research partners.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital patient recruitment and clinical trial matching company connecting patients to trials through machine learning. Closely comparable to Anova's free AI patient matching solution and the broader site/patient matching value proposition, with overlap in biopharma and patient-direct channels.

TypeBroad incumbent
Description

Global full-service CRO and life-sciences technology vendor with extensive clinical trial management, patient recruitment, and real-world evidence capabilities. Comparable to Anova as a sponsor-facing CRO with technology-enabled services, but at vastly larger scale and broader portfolio.

TypeBroad incumbent
Description

Large global CRO offering clinical development and commercial services across all phases. Comparable to Anova as a clinical CRO serving biopharma sponsors, including patient recruitment and site activation workflows, though with a much larger employee base and global delivery footprint.

TypeBroad incumbent
Description

Top-tier global CRO providing outsourced drug development and clinical trial services. Comparable to Anova as a clinical CRO targeting biopharma sponsors across therapeutic areas, though serving at significantly larger enterprise scale.

TypeEmerging player
Description

Technology-focused clinical trial platform offering eCOA, telehealth, and decentralized trial capabilities, including patient matching and site enablement. Comparable to Anova as a tech-enabled trial enablement vendor overlapping on patient recruitment and remote monitoring, though Medable focuses on DCT workflows rather than full-service CRO.

TypeBroad incumbent
Description

Life-sciences cloud vendor offering CTMS, EDC, eTMF, and clinical data management software. Comparable to Anova on the clinical trial informatics layer (CTMS/EDC/eTMF overlap with AnovaOS modules) and target sponsor customer base, but as a software vendor rather than a CRO.

TypeBroad incumbent
Description

Industry-standard clinical trial technology platform (Rave EDC, CTMS, eCOA, RTSM) serving biopharma sponsors and CROs. Comparable to Anova on clinical trial informatics, data capture, and trial enablement, with substantial overlap in biopharma customers.

TypeEmerging player
Description

Decentralized clinical trial operating company combining technology and telemedicine for site-less and remote trials. Comparable to Anova on patient recruitment, remote monitoring, and tech-enabled trial enablement, with overlap in biopharma oncology and rare-disease sponsors.

TypeEmerging player
Description

Cloud-based clinical data capture platform with eCRF, EDC, ePRO, and decentralized trial features used by sponsors and CROs. Comparable to Anova on clinical data management and trial enablement tooling, though positioned as a data-capture software vendor rather than full-service CRO.

TypeEmerging player
Description

AI-driven patient recruitment and trial feasibility platform for sponsors and CROs. Directly comparable to Anova's AI patient matching and digital feasibility modules, focused narrowly on recruitment and protocol feasibility.

Market position
Strengths6 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anova Enterprises

Clinical Trial Technologyanovaevidence.com

Anova Enterprises is a technology-enabled CRO operating the AnovaOS™ platform, which connects biopharma sponsors, research sites, and patients to accelerate clinical trial design, site activation, patient matching, and enrollment across oncology, neurology, urology, and rare diseases.

What Anova Enterprises does

Anova Enterprises is a privately held, technology-enabled contract research organization (CRO) founded in 2017 and headquartered in Schaumburg, Illinois, with an additional UK office in London. The company operates the AnovaOS™ platform, an integrated clinical research network that connects 15,000+ sponsors, 130,000+ active studies, 15,000+ investigational products, 40,000+ research sites, and 100,000+ investigators, with the stated goal of accelerating clinical development for oncology, neurology, urology, infectious disease, immunology, cardiology, and rare disease therapeutics.

The AnovaOS platform comprises interconnected modules covering protocol structuring and eligibility codification, site and physician qualification, patient matching, site activation (advertised as 5 working days via master contract and fee schedule), data capture, and essential document management. In 2025, the company launched a free AI-enabled patient matching solution covering 200,000+ open trials and a 21 CFR Part 11 compliant Global Clinical Registry, and scaled a Virtual Urology Research Network to 500+ active sites. The platform is HIPAA and 21 CFR Part 11 compliant, supporting both interventional trials and compassionate use programs.

Anova's business model combines enterprise services and platform subscriptions targeted at biopharmaceutical sponsors and CROs, complemented by a self-serve, free AI patient-matching funnel for patients and individual research sites. Pricing is quote-based and not publicly disclosed. The company generates revenue through technology-enabled CRO engagements, including ongoing programs with Denovo Biopharma (DB107 gene therapy in high-grade glioma, supported by an $11.8M CIRM grant), NeOnc Technologies (NEO212, NEO100), and Dizal Pharmaceuticals (DZD9008 for EGFR Exon20ins NSCLC). Leadership includes co-founders Chris Beardmore (CEO) and Martin Walsh (President), with senior executives added in 2025 including CMO Dr. Fred Ma, VP Clinical Development Adam Callahan, and CFO Rhonda Rosen.

Anova Enterprises firmographics

Firmographics
Name
Anova Enterprises
Legal name
Anova Enterprises, Inc.
Website
https://anovaevidence.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Anova Enterprises is a technology-enabled CRO operating the AnovaOS™ platform, which connects biopharma sponsors, research sites, and patients to accelerate clinical trial design, site activation, patient matching, and enrollment across oncology, neurology, urology, and rare diseases.
Ownership category
akta.pro rank

Anova Enterprises industry classification

Industry
Product category
Clinical Trial Technology
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Custom Computer Programming Services (541511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Clinical trial technology
  • Patient matching platform
  • Contract research services
  • Clinical site activation
  • Real-world evidence registry

Where Anova Enterprises is headquartered

Location

Headquarters

HQ city
Arlington Heights
HQ country
United States
HQ region
North America

Markets served

Anova Enterprises business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Distribution channels3 records

Marketing channels4 records

Anova Enterprises product offering

Product offering

Core offering

Anova Enterprises operates AnovaOS™, a proprietary technology-enabled CRO platform that connects biopharmaceutical sponsors, research sites, physicians, and patients to accelerate clinical development. The platform delivers AI-enabled patient matching, digital feasibility assessments, automated site activation, remote monitoring, document/data management, and a global clinical registry across an integrated network of 40,000+ research sites and 100,000+ investigators. Anova supplements the platform with full-service CRO engagements and consulting for therapeutic areas including oncology, neurology, immunology, cardiology, infectious disease, and rare disease.

Product overview

Anova Enterprises offers AnovaOS™, a unified clinical research technology platform that integrates an ecosystem of sponsors, research sites, physicians, and patients for accelerated clinical development. The platform comprises multiple interconnected modules including patient matching and enrollment, site activation, data capture and evidence generation, essential document management, and a global clinical registry. Additional offerings include a free AI-enabled patient matching solution using proprietary algorithms, a Network Powered Patient Registry study (NCT05013944) for real-world evidence, and a Virtual Urology Research Network sub-network with 500+ sites. The platform supports both clinical trials and compassionate use programs, enabling just-in-time access to any investigational product.

Differentiator

Problem solved

Functional benefit

Brands

  • AnovaOS: Proprietary clinical research technology platform providing an integrated research network of sponsors, studies, investigational products, research sites, and investigators. Enables patient matching, site activation, and clinical trial management.

Products and services

  • AnovaOS™ Platform Clinical research technology platform providing an integrated research network that connects sponsors, research sites, physicians, and patients. Enables study feasibility, patient matching, site activation, patient enrollment, data capture, and compassionate use program management for biopharmaceutical sponsors and research sites.
  • AnovaOS® Global Clinical Registry 21 CFR Part 11 compliant global clinical registry providing real-world evidence about research sites and patients, administrative efficiency in research conduct, post-market surveillance, and data-driven study design support for sponsors and research sites.
  • AI-Enabled Patient Matching Solution Free AI-powered patient matching solution using proprietary algorithms to connect patients to over 200,000+ open clinical trials with high-confidence eligibility matching. Automates screening and integrates into study coordination workflows for patients and participating research sites.
  • Network Powered Patient Registry Global patient registry study (NCT05013944) capturing clinically meaningful real-world data on patient diagnosis, nature, course of infection, treatment(s), and outcomes for patients with complex and rare diseases, available to sponsors and research sites through the AnovaOS network.
  • Virtual Urology Research Network Virtual urology research network of 500+ quality-confirmed research sites enabling rapid site-to-study matching, streamlined study start-up, and faster patient enrollment for urology clinical research programs.
  • Clinical Development & Technical Consulting Services Consultancy services to accelerate clinical development and technical services for data integration, advanced analytics, and clinical evidence generation for biopharmaceutical sponsors and research partners.

Quantifiable outcome

  • Free AI-enabled patient matching solution available to patients

Companies that use Anova Enterprises

Customer profile

Segments4 records

Ideal customer profiles4 records

Anova Enterprises technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Anova Enterprises partnerships and signals

Strategic signal

Recent moves8 records

Expansion highlights7 records

Anova Enterprises competitors and assessment

Company assessment

Emerging players

  • Antidote Technologies: Digital patient recruitment and clinical trial matching company connecting patients to trials through machine learning. Closely comparable to Anova's free AI patient matching solution and the broader site/patient matching value proposition, with overlap in biopharma and patient-direct channels.
  • Medable: Technology-focused clinical trial platform offering eCOA, telehealth, and decentralized trial capabilities, including patient matching and site enablement. Comparable to Anova as a tech-enabled trial enablement vendor overlapping on patient recruitment and remote monitoring, though Medable focuses on DCT workflows rather than full-service CRO.
  • Science 37: Decentralized clinical trial operating company combining technology and telemedicine for site-less and remote trials. Comparable to Anova on patient recruitment, remote monitoring, and tech-enabled trial enablement, with overlap in biopharma oncology and rare-disease sponsors.
  • Castor EDC: Cloud-based clinical data capture platform with eCRF, EDC, ePRO, and decentralized trial features used by sponsors and CROs. Comparable to Anova on clinical data management and trial enablement tooling, though positioned as a data-capture software vendor rather than full-service CRO.
  • Trial Library: AI-driven patient recruitment and trial feasibility platform for sponsors and CROs. Directly comparable to Anova's AI patient matching and digital feasibility modules, focused narrowly on recruitment and protocol feasibility.

Broad incumbents

  • IQVIA: Global full-service CRO and life-sciences technology vendor with extensive clinical trial management, patient recruitment, and real-world evidence capabilities. Comparable to Anova as a sponsor-facing CRO with technology-enabled services, but at vastly larger scale and broader portfolio.
  • Syneos Health: Large global CRO offering clinical development and commercial services across all phases. Comparable to Anova as a clinical CRO serving biopharma sponsors, including patient recruitment and site activation workflows, though with a much larger employee base and global delivery footprint.
  • ICON plc: Top-tier global CRO providing outsourced drug development and clinical trial services. Comparable to Anova as a clinical CRO targeting biopharma sponsors across therapeutic areas, though serving at significantly larger enterprise scale.
  • Veeva Systems: Life-sciences cloud vendor offering CTMS, EDC, eTMF, and clinical data management software. Comparable to Anova on the clinical trial informatics layer (CTMS/EDC/eTMF overlap with AnovaOS modules) and target sponsor customer base, but as a software vendor rather than a CRO.
  • Medidata (Dassault Systèmes): Industry-standard clinical trial technology platform (Rave EDC, CTMS, eCOA, RTSM) serving biopharma sponsors and CROs. Comparable to Anova on clinical trial informatics, data capture, and trial enablement, with substantial overlap in biopharma customers.

Market position

Strengths6 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Anova Enterprises social profiles

Digital presence

Anova Enterprises compliance and trust

Trust signal

Compliance2 records

Anova Enterprises financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anova Enterprises leadership team

Management profile

Number of profiles

Profiles9 records

Anova Enterprises funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anova Enterprises M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anova Enterprises

What does Anova Enterprises do?

Anova Enterprises operates AnovaOS™, a proprietary technology-enabled CRO platform that connects biopharmaceutical sponsors, research sites, physicians, and patients to accelerate clinical development. The platform delivers AI-enabled patient matching, digital feasibility assessments, automated site activation, remote monitoring, document/data management, and a global clinical registry across an integrated network of 40,000+ research sites and 100,000+ investigators. Anova supplements the platform with full-service CRO engagements and consulting for therapeutic areas including oncology, neurology, immunology, cardiology, infectious disease, and rare disease.

Is Anova Enterprises a public or private company?

Anova Enterprises is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Anova Enterprises founded?

Anova Enterprises was founded in 2017. It employs 11 to 50 people.

Where is Anova Enterprises based?

Anova Enterprises is headquartered in Arlington Heights, United States, in the North America region.

Who are Anova Enterprises's main competitors?

Emerging players on record are Antidote Technologies, Medable, Science 37, Castor EDC and Trial Library. Broad incumbents are IQVIA, Syneos Health, ICON plc, Veeva Systems and Medidata (Dassault Systèmes).

Does Anova Enterprises have an API?

No public API is recorded for Anova Enterprises.

What industry is Anova Enterprises in?

Anova Enterprises's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAnova Expands Platform With Launch of Next-Generation eTMF Solution for Sponsors, CROs, and Research SitesAnova Enterprises, Inc. announced the launch of its next-generation electronic Trial Master File (eTMF) platform as part of the AnovaOS® unified clinical operations environment. The platform combines document automation, eISFs, integrated eSignature, and workflow management to eliminate manual tasks and improve compliance between sponsors, CROs, and research sites. Investigative sites can access the platform free of licensing fees, and Anova continues to invest in AI-driven automation capabilities including predictive document tracking and risk-based quality management workflows.Business Wire BlogFive Hundredth Urology Research Site Joins Anova’s Global Urology Research NetworkAnova Enterprises announced its 500th urology research site has joined its virtual network, making it the largest digitally connected urology research ecosystem. The network uses AnovaOS technology to streamline study operations and accelerate patient enrollment. Anova plans continued expansion and disease-specific sub-networks.Business Wire BlogAnova Launches Free AI-enabled Clinical Trial Patient Matching Solution as Part of a Global Just-in-time Research NetworkAnova Enterprises, Inc. has launched a free AI-enabled patient matching solution designed to connect patients with over 200,000 open clinical trials using proprietary algorithms for high-confidence eligibility screening. This initiative is part of a global just-in-time research network intended to accelerate trial enrollment by automating the screening process and integrating into existing study coordination workflows. The move aims to remove cost barriers for research sites, thereby fostering broader participation in clinical research and speeding up the availability of new therapies.BioSpaceAnova Today Announced the Enrollment of 550+ Patients at 50+ Sites in Six Months for a Single StudyAnova Enterprises, Inc. announced the completion of enrollment for 550+ patients at 50+ clinical sites in just six months for a single intermediate-sized, treatment IND study in oncology, using its proprietary AnovaOS™ platform. The study provided cancer patients with access to a promising treatment while delivering safety and efficacy data to the sponsor to support drug development. AI-driven patient matching, digitized workflows, and real-time performance oversight enabled the company to outperform traditional industry timelines at lower cost, demonstrating the operational efficiency of its connected research systems.GlobeNewswireNeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®NeOnc Technologies expanded its engagement with Anova Enterprises to pursue a pediatric indication for NEO100, an intranasal drug delivery system for pediatric high-grade gliomas. Anova will prepare the FDA Fast-Track and Rare Pediatric Designation application, building on NEO100's adult success. The company expects to collect sufficient data to demonstrate therapeutic value for pHGGS.